$PIII
P3 Health Partners Inc. Stock $piii

$piii Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000162828024047186 Filed on November 12, 2024

Income Statement

Concept	2024 Q3
Revenue	$362.1M
YoY Change	25.58%
Cost Of Revenue	$401.9M
YoY Change	43.95%
Gross Profit	-$39.80M
YoY Change	-537.32%
Gross Profit Margin	-10.99%
Selling, General & Admin	$27.35M
YoY Change	-18.88%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$600.0K
YoY Change	20.0%
% of Gross Profit
Operating Expenses	$469.1M
YoY Change	45.61%
Operating Profit	-$107.0M
YoY Change	216.35%
Interest Expense	-$5.647M
YoY Change	41.18%
% of Operating Profit
Other Income/Expense, Net	$535.0K
YoY Change	-117.5%
Pretax Income	-$106.5M
YoY Change	188.68%
Income Tax	-$3.605M
% Of Pretax Income
Net Earnings	-$46.51M
YoY Change	249.82%
Net Earnings / Revenue	-12.84%
Basic Earnings Per Share	-$0.29
Diluted Earnings Per Share	-$0.31
COMMON SHARES
Basic Shares Outstanding	161.9M shares
Diluted Shares Outstanding	164.7M shares

Balance Sheet

Concept	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$62.96M
YoY Change	19.7%
Cash & Equivalents	$63.00M
Short-Term Investments
Other Short-Term Assets	$26.29M
YoY Change	241.44%
Inventory
Prepaid Expenses
Receivables	$123.3M
Other Receivables	$2.495M
Total Short-Term Assets	$215.1M
YoY Change	19.71%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.315M
YoY Change	-32.53%
Goodwill
YoY Change
Intangibles	$594.9M
YoY Change	-13.52%
Long-Term Investments
YoY Change
Other Assets	$17.08M
YoY Change	-14.57%
Total Long-Term Assets	$618.3M
YoY Change	-13.8%
TOTAL ASSETS
Total Short-Term Assets	$215.1M
Total Long-Term Assets	$618.3M
Total Assets	$833.3M
YoY Change	-7.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$13.47M
YoY Change	15.8%
Accrued Expenses	$49.21M
YoY Change	134.79%
Deferred Revenue
YoY Change
Short-Term Debt	$208.0K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$405.3M
YoY Change	51.63%
LONG-TERM LIABILITIES
Long-Term Debt	$133.2M
YoY Change	23.07%
Other Long-Term Liabilities	$30.88M
YoY Change	52.1%
Total Long-Term Liabilities	$133.2M
YoY Change	23.07%
TOTAL LIABILITIES
Total Short-Term Liabilities	$405.3M
Total Long-Term Liabilities	$133.2M
Total Liabilities	$569.4M
YoY Change	43.84%
SHAREHOLDERS EQUITY
Retained Earnings	-$444.6M
YoY Change	30.04%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$120.5M
YoY Change
Total Liabilities & Shareholders Equity	$833.3M
YoY Change	-7.09%

Cashflow Statement

Concept	2024 Q3
OPERATING ACTIVITIES
Net Income	-$46.51M
YoY Change	249.82%
Depreciation, Depletion And Amortization	$600.0K
YoY Change	20.0%
Cash From Operating Activities	-$22.62M
YoY Change	198.0%
INVESTING ACTIVITIES
Capital Expenditures	$0.00
YoY Change	-100.0%
Acquisitions
YoY Change
Other Investing Activities	$15.00M
YoY Change
Cash From Investing Activities	$15.00M
YoY Change	-3946.15%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-2.486M
YoY Change	2662.22%
NET CHANGE
Cash From Operating Activities	-22.62M
Cash From Investing Activities	15.00M
Cash From Financing Activities	-2.486M
Net Change In Cash	-10.10M
YoY Change	25.2%
FREE CASH FLOW
Cash From Operating Activities	-$22.62M
Capital Expenditures	$0.00
Free Cash Flow	-$22.62M
YoY Change	183.43%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	89074
	dei	City Area Code CityAreaCode	702
	dei	Local Phone Number LocalPhoneNumber	910-3950(Registrant’s telephone number, including area code)
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36320000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	4614000	usd
CY2024Q3	piii	Health Plan Settlement Receivables Allowance For Credit Loss Current HealthPlanSettlementReceivablesAllowanceForCreditLossCurrent	150000	usd
CY2023Q4	piii	Health Plan Settlement Receivables Current HealthPlanSettlementReceivablesCurrent	118497000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3613000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	215073000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6315000	usd
CY2024Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	594865000	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	17080000	usd
CY2024Q3	us-gaap	Assets Assets	833333000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	13468000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	49205000	usd
CY2024Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4409000	usd
CY2024Q3	piii	Claims Payable Current ClaimsPayableCurrent	230736000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	322171000	usd
	us-gaap	Operating Expenses OperatingExpenses	1311924000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-106990000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-33820000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-182155000	usd
CY2024Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-5647000	usd
CY2023Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-4002000	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-15339000	usd
CY2024Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-5737000	usd
CY2023Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-755000	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-106455000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-36877000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-181795000	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3605000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	412000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-565000	usd
CY2024Q3	us-gaap	Profit Loss ProfitLoss	-102850000	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-37289000	usd
	us-gaap	Profit Loss ProfitLoss	-181230000	usd
	us-gaap	Profit Loss ProfitLoss	-117319000	usd
CY2024Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-56338000	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-23993000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-103998000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-85008000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-46512000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-13296000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-77232000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-32311000	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.29
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.55
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.31
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.12
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.64
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.41
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	161890000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	114198000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	139292000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	88010000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	288379000	shares
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	516805000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	5854000	usd
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Entity Registrant Name EntityRegistrantName	P3 Health Partners Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-2992794
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2370 Corporate Circle Suite 300
	dei	Entity Address City Or Town EntityAddressCityOrTown	Henderson
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NV
CY2024Q3	piii	Health Plans Settlements Payable Current HealthPlansSettlementsPayableCurrent	41169000	usd
CY2024Q3	piii	Premium Deficiency Reserve Current PremiumDeficiencyReserveCurrent	29441000	usd
CY2024Q3	us-gaap	Interest Payable Current InterestPayableCurrent	35929000	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	469114000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-14626000	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	445000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	190000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1073000	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	535000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3057000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	360000	usd
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	164701000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	312679000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	141723000	shares
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	362124000	usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001832511
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	62962000	usd
CY2024Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	5136000	usd
CY2023Q4	piii	Health Plan Settlement Receivables Allowance For Credit Loss Current HealthPlanSettlementReceivablesAllowanceForCreditLossCurrent	150000	usd
CY2024Q3	piii	Health Plan Settlement Receivables Current HealthPlanSettlementReceivablesCurrent	123325000	usd
CY2024Q3	piii	Clinic Fees And Insurance Receivables Net Current ClinicFeesAndInsuranceReceivablesNetCurrent	2495000	usd
CY2023Q4	piii	Clinic Fees And Insurance Receivables Net Current ClinicFeesAndInsuranceReceivablesNetCurrent	2973000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11032000	usd
CY2023Q4	us-gaap	Accounts Payable Noncurrent Related Party Type Extensible Enumeration AccountsPayableNoncurrentRelatedPartyTypeExtensibleEnumeration	http://fasb.org/srt/2023#AffiliatedEntityMember
CY2024Q3	us-gaap	Accounts Payable Noncurrent Related Party Type Extensible Enumeration AccountsPayableNoncurrentRelatedPartyTypeExtensibleEnumeration	http://fasb.org/srt/2023#AffiliatedEntityMember
CY2024Q3	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	10123000	usd
CY2023Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	0	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	166017000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8686000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	666733000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	19531000	usd
CY2023Q4	us-gaap	Assets Assets	860967000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8663000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	36884000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3506000	usd
CY2023Q4	piii	Health Plans Settlements Payable Current HealthPlansSettlementsPayableCurrent	34992000	usd
CY2023Q4	piii	Claims Payable Current ClaimsPayableCurrent	178009000	usd
CY2023Q4	piii	Premium Deficiency Reserve Current PremiumDeficiencyReserveCurrent	13670000	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	23648000	usd
CY2024Q3	us-gaap	Short Term Borrowings ShortTermBorrowings	208000	usd
CY2023Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	0	usd
CY2024Q3	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	753000	usd
CY2023Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	0	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	405318000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	299372000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	11158000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	13622000	usd
CY2024Q3	piii	Warrant Liabilities Noncurrent WarrantLiabilitiesNoncurrent	19718000	usd
CY2023Q4	piii	Warrant Liabilities Noncurrent WarrantLiabilitiesNoncurrent	1085000	usd
CY2024Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	0	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	4907000	usd
CY2024Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	133228000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	108319000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	569422000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	427305000	usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	143397000	usd
CY2023Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	291532000	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	565054000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	509442000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-444576000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-367344000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	120514000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	142130000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	833333000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	860967000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	288351000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1129769000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	919514000	usd
CY2024Q3	piii	Medical Expenses MedicalExpenses	401920000	usd
CY2023Q3	piii	Medical Expenses MedicalExpenses	279220000	usd
	piii	Medical Expenses MedicalExpenses	1149148000	usd
	piii	Medical Expenses MedicalExpenses	867061000	usd
CY2024Q3	piii	Premium Deficiency Testing Expense Long Duration Contract Amount1 PremiumDeficiencyTestingExpenseLongDurationContractAmount1	18168000	usd
CY2023Q3	piii	Premium Deficiency Testing Expense Long Duration Contract Amount1 PremiumDeficiencyTestingExpenseLongDurationContractAmount1	-12489000	usd
	piii	Premium Deficiency Testing Expense Long Duration Contract Amount1 PremiumDeficiencyTestingExpenseLongDurationContractAmount1	15771000	usd
	piii	Premium Deficiency Testing Expense Long Duration Contract Amount1 PremiumDeficiencyTestingExpenseLongDurationContractAmount1	-9361000	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	27219000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	33065000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	81230000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	97931000	usd
CY2024Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	134000	usd
CY2023Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	654000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	870000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2512000	usd
CY2024Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	21673000	usd
CY2023Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	21721000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	64905000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	65041000	usd
	us-gaap	Operating Expenses OperatingExpenses	1023184000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-103670000	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-11939000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	327000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-455000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-12721000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-116391000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	928000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	686000	usd
CY2023Q1	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	-9199000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-2685000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	740000	usd
CY2023Q2	piii	Adjustments To Additional Paid In Capital Fair Value Adjustment Redeemable Non Controlling Interest AdjustmentsToAdditionalPaidInCapitalFairValueAdjustmentRedeemableNonControllingInterest	-330617000	usd
CY2023Q2	piii	Adjustment To Equity Remeasurement Adjustment AdjustmentToEquityRemeasurementAdjustment	119630000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	86582000	usd
CY2023Q2	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	-9816000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-136166000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2146000	usd
CY2023Q3	piii	Restricted Stock Units Transaction Bonus RestrictedStockUnitsTransactionBonus	5000000	usd
CY2023Q3	piii	Adjustments To Additional Paid In Capital Fair Value Adjustment Redeemable Non Controlling Interest AdjustmentsToAdditionalPaidInCapitalFairValueAdjustmentRedeemableNonControllingInterest	330617000	usd
CY2023Q3	piii	Adjustment To Equity Remeasurement Adjustment AdjustmentToEquityRemeasurementAdjustment	-358000	usd
CY2023Q3	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	-13296000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	187943000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	142130000	usd
CY2024Q1	piii	Stock Issued During The Period Settlement Of Restricted Stock Units Net Of Shares Withheld For Tax Value StockIssuedDuringThePeriodSettlementOfRestrictedStockUnitsNetOfSharesWithheldForTaxValue	-73000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1449000	usd
CY2024Q1	piii	Adjustments To Additional Paid In Capital Fair Value Adjustment Redeemable Non Controlling Interest AdjustmentsToAdditionalPaidInCapitalFairValueAdjustmentRedeemableNonControllingInterest	20579000	usd
CY2024Q1	piii	Adjustment To Equity Remeasurement Adjustment AdjustmentToEquityRemeasurementAdjustment	1211000	usd
CY2024Q1	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	-18700000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	146596000	usd
CY2024Q2	piii	Stock Issued During The Period Settlement Of Restricted Stock Units Net Of Shares Withheld For Tax Value StockIssuedDuringThePeriodSettlementOfRestrictedStockUnitsNetOfSharesWithheldForTaxValue	-30000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1624000	usd
CY2024Q2	piii	Adjustment To Equity Remeasurement Adjustment AdjustmentToEquityRemeasurementAdjustment	24095000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	6575000	usd
CY2024Q2	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	-12020000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	166840000	usd
CY2024Q3	piii	Stock Issued During The Period Settlement Of Restricted Stock Units Net Of Shares Withheld For Tax Value StockIssuedDuringThePeriodSettlementOfRestrictedStockUnitsNetOfSharesWithheldForTaxValue	-24000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1958000	usd
CY2024Q3	piii	Adjustment To Equity Remeasurement Adjustment AdjustmentToEquityRemeasurementAdjustment	-1748000	usd
CY2024Q3	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	-46512000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	120514000	usd
	us-gaap	Profit Loss ProfitLoss	-181230000	usd
	us-gaap	Profit Loss ProfitLoss	-117319000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	64905000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	65041000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	5031000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	4259000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	13000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	405000	usd
	piii	Accretion Of Contingent Consideration AccretionOfContingentConsideration	0	usd
	piii	Accretion Of Contingent Consideration AccretionOfContingentConsideration	113000	usd
	piii	Gain On Write Off Of Contingent Consideration GainOnWriteOffOfContingentConsideration	4907000	usd
	piii	Gain On Write Off Of Contingent Consideration GainOnWriteOffOfContingentConsideration	0	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-14626000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	327000	usd
	piii	Premium Deficiency Testing Expense Long Duration Contract Amount1 PremiumDeficiencyTestingExpenseLongDurationContractAmount1	15771000	usd
	piii	Premium Deficiency Testing Expense Long Duration Contract Amount1 PremiumDeficiencyTestingExpenseLongDurationContractAmount1	-9361000	usd
	piii	Increase Decrease In Health Plan Receivables Premiums IncreaseDecreaseInHealthPlanReceivablesPremiums	4828000	usd
	piii	Increase Decrease In Health Plan Receivables Premiums IncreaseDecreaseInHealthPlanReceivablesPremiums	45258000	usd
	piii	Increase Decrease In Clinic Fees Insurance And Other Receivables IncreaseDecreaseInClinicFeesInsuranceAndOtherReceivables	-445000	usd
	piii	Increase Decrease In Clinic Fees Insurance And Other Receivables IncreaseDecreaseInClinicFeesInsuranceAndOtherReceivables	-5275000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	7402000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	429000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	2000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1214000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1780000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2758000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	903000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	2405000	usd
	piii	Increase Decrease In Health Plan Payables Premiums IncreaseDecreaseInHealthPlanPayablesPremiums	6177000	usd
	piii	Increase Decrease In Health Plan Payables Premiums IncreaseDecreaseInHealthPlanPayablesPremiums	21814000	usd
	piii	Increase Decrease In Claims Payable IncreaseDecreaseInClaimsPayable	52727000	usd
	piii	Increase Decrease In Claims Payable IncreaseDecreaseInClaimsPayable	4290000	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	12281000	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	7092000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	72000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-348000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-52890000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-60150000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2039000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	15000000	usd
CY2023Q3	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	15000000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2039000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	25000000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	14101000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	100000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	173000	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	40547000	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	87244000	usd
	piii	Proceeds From Issuance Of Common Stock Net Of Offering Cost ProceedsFromIssuanceOfCommonStockNetOfOfferingCost	33000	usd
	piii	Proceeds From Issuance Of Common Stock Net Of Offering Cost ProceedsFromIssuanceOfCommonStockNetOfOfferingCost	0	usd
	piii	Deferred Offering Costs Paid DeferredOfferingCostsPaid	507000	usd
	piii	Deferred Offering Costs Paid DeferredOfferingCostsPaid	0	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	127000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1663000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	usd
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	1871000	usd
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	65054000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	101172000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	27164000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	38983000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	40934000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18457000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	68098000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	57440000	usd
CY2024Q3	us-gaap	Profit Loss ProfitLoss	-102900000	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-37300000	usd
	us-gaap	Profit Loss ProfitLoss	-181200000	usd
	us-gaap	Profit Loss ProfitLoss	-117300000	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	63000000.0	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36300000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of these unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that could affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates, including, but not limited to, those related to allowance for credit losses, revenue recognition, the liability for unpaid claims, equity-based compensation, premium deficiency reserves (“PDR”), fair value and impairment recognition of long-lived assets </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(including intangibles), fair value of liability classified instruments, and judgments related to deferred income taxes. The Company bases its estimates on the best information available at the time, its experiences, and various other assumptions believed to be reasonable under the circumstances. Actual results could differ from those estimates.</span></div>
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	362124000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	288351000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1129769000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	919514000	usd
CY2024Q3	piii	Number Of Customers NumberOfCustomers	5	customer
	piii	Number Of Customers NumberOfCustomers	4	customer
	piii	Number Of Customers NumberOfCustomers	3	customer
CY2023	piii	Number Of Customers NumberOfCustomers	3	customer
CY2024Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	19296000	usd
CY2023Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	51000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12588000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13467000	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6273000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4781000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6315000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8686000	usd
CY2024Q3	us-gaap	Depreciation Depreciation	600000	usd
CY2023Q3	us-gaap	Depreciation Depreciation	500000	usd
CY2023Q3	us-gaap	Depreciation Depreciation	500000	usd
	us-gaap	Depreciation Depreciation	1700000	usd
	us-gaap	Depreciation Depreciation	1800000	usd
CY2024Q3	us-gaap	Assets Held For Sale Not Part Of Disposal Group AssetsHeldForSaleNotPartOfDisposalGroup	15000000	usd
CY2024Q3	us-gaap	Deposit Liability Current DepositLiabilityCurrent	15000000	usd
CY2024Q3	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	830587000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	235722000	usd
CY2024Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	594865000	usd
CY2024Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	594865000	usd
CY2023Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	842835000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	176102000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	666733000	usd
CY2024Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	21000000.0	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	21100000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	63100000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	63200000	usd
CY2024Q3	piii	Short Term Borrowings Due Period Three ShortTermBorrowingsDuePeriodThree	200000	usd
CY2024Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	134477000	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	109102000	usd
CY2024Q3	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	1249000	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	783000	usd
CY2024Q3	us-gaap	Long Term Debt LongTermDebt	133228000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	108319000	usd
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	164701000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	312679000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	141723000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	288379000	shares
CY2024Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	335209000	shares
CY2023Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	92745000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	335209000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	92745000	shares
	piii	Common Units Exchanged Or Redeemed In Period CommonUnitsExchangedOrRedeemedInPeriod	600000	shares
	piii	Common Units Exchanged Or Redeemed In Period CommonUnitsExchangedOrRedeemedInPeriod	3500000	shares
	piii	Redeemable Noncontrolling Interest Equity Fair Value Remeasurement Adjustment RedeemableNoncontrollingInterestEquityFairValueRemeasurementAdjustment	0	usd
	piii	Redeemable Noncontrolling Interest Equity Fair Value Remeasurement Adjustment RedeemableNoncontrollingInterestEquityFairValueRemeasurementAdjustment	0	usd
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2024Q2	piii	Ownership Interest Contigency Trigger Percentage OwnershipInterestContigencyTriggerPercentage	0.40
CY2024Q2	piii	Maximum Amount Of Shares Owned By Related Party MaximumAmountOfSharesOwnedByRelatedParty	0.4999
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001628280-24-047186-index-headers.html	Edgar Link	pending
0001628280-24-047186-index.html	Edgar Link	pending
0001628280-24-047186.txt	Edgar Link	pending
0001628280-24-047186-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
piii-20240930.htm	Edgar Link	pending
piii-20240930.xsd	Edgar Link	pending
piii-20240930xex101.htm	Edgar Link	pending
piii-20240930xex102.htm	Edgar Link	pending
piii-20240930xex103.htm	Edgar Link	pending
piii-20240930xex311.htm	Edgar Link	pending
piii-20240930xex312.htm	Edgar Link	pending
piii-20240930xex321.htm	Edgar Link	pending
piii-20240930xex322.htm	Edgar Link	pending
piii-20240930_g1.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
piii-20240930_cal.xml	Edgar Link	unprocessable
piii-20240930_def.xml	Edgar Link	unprocessable
piii-20240930_lab.xml	Edgar Link	unprocessable
piii-20240930_pre.xml	Edgar Link	unprocessable
piii-20240930_htm.xml	Edgar Link	completed
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PIII
P3 Health Partners Inc. Stock $piii

2024 Q3 Form 10-Q Financial Statement

#000162828024047186 Filed on November 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PIII P3 Health Partners Inc. Stock $piii

2024 Q3 Form 10-Q Financial Statement

#000162828024047186 Filed on November 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PIII
P3 Health Partners Inc. Stock $piii